Welcome to Asuragen Diagnostics
Asuragen is a fully integrated diagnostic development company and pharmaceutical services provider.
The Company’s product portfolio consists of the first-ever validated microRNA testing service for pancreatic
cancer, multiplex quantitative RNA-based assays, innovative solutions for the detection of the fragile X mental
retardation gene (FMR1), Signature® Oncology products for the qualitative detection of gene translocations and
mutations, RNA stabilization technologies, and industry-leading controls and standards engineered using its
patented Armored RNA® technology. In addition, Asuragen offers the full range of contract manufacturing services
for high quality reagents from plasmid DNA to in vitro synthesized RNA and complex multi-step assays.
Asuragen is empowered with a high level of scientific expertise and assay development capabilities, CLIA and GLP testing
services, and an established cGMP manufacturing facility, which allow it to span the spectrum of discovery, testing,
production and commercialization. Asuragen is dedicated to developing new technologies that will become cutting
edge clinical products.